Results from the Phase 3 BREAKWATER trial suggest a new first-line treatment approach for metastatic colorectal cancer with the BRAF V600E mutation. Using targeted therapy early can significantly improve outcomes for patients with this aggressive form of cancer.
The treatment combines encorafenib (Braftovi), cetuximab (Erbitux), and fluorouracil-based chemotherapy. In the trial, the combination achieved an objective response rate of 64%, compared with 39% for standard chemotherapy. Researchers say starting targeted therapy earlier may also prevent some patients from becoming too ill to receive additional treatments later.
The study also highlights the growing importance of molecular testing when colorectal cancer is first diagnosed. Treatment choices increasingly depend on tumor biomarkers such as BRAF V600E, KRAS status, and HER2 expression. As more targeted therapies move to earlier treatment lines, later-line therapy decisions are becoming more complex and may rely more on clinical trials, newer drugs like fruquintinib, and updated molecular testing at disease progression.